Related Experiment Videos
Antiplatelet activity of inositol hexaphosphate (IP6)
I Vucenik1, J J Podczasy, A M Shamsuddin
1Department of Medical and Research Technology, University of Maryland School of Medicine Baltimore 21201, USA.
Anticancer Research
|January 8, 2000
Summary
Inositol hexaphosphate (IP6) effectively inhibits platelet aggregation and adenosine triphosphate (ATP) release in human blood. This finding suggests IP6 may help reduce the risk of cardiovascular diseases like thrombosis and atherosclerosis.
Area of Science:
- Biochemistry
- Hematology
- Pharmacology
Background:
- Platelet activation is crucial in thrombosis and atherosclerosis pathogenesis.
- Inositol hexaphosphate (IP6) is investigated for its potential biological effects.
Purpose of the Study:
- To investigate the effect of IP6 on human platelet aggregation and adenosine triphosphate (ATP) release.
- To assess IP6's potential role in cardiovascular disease prevention.
Main Methods:
- Whole blood from healthy volunteers was used.
- Platelet aggregation and ATP release were measured using impedance technology.
- Platelets were activated by adenosine diphosphate (ADP), collagen, or thrombin in the presence or absence of IP6.
Main Results:
- IP6 significantly inhibited platelet aggregation induced by ADP, collagen, and thrombin in a dose-dependent manner.
- IP6 markedly reduced agonist-induced ATP release from platelet dense granules.
- IC50 values for IP6 inhibition of aggregation were 0.9 mM (ADP), 1.6 mM (collagen), and 0.8 mM (thrombin).
Conclusions:
- IP6 demonstrates potent in vitro inhibition of human platelet aggregation.
- IP6 effectively reduces platelet activation and mediator release.
- IP6 shows potential as a therapeutic agent for reducing cardiovascular disease risk.